Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Pharma and biotech ETFs are in great shape and are trading at a one-month high level.